Kymera Therapeutics announces first patient dosed in Phase 2 trial of KT-474

Kymera Therapeutics (KYMR) announced that the first patient has been dosed in the randomized Phase 2 clinical trial in hidradenitis suppurativa evaluating KT-474, a first-in-class, investigational IRAK4 degrader. The Phase 2 study will evaluate the efficacy, safety, pharmacokinetics, and biological effects of KT-474 compared with placebo in adult patients with moderate to severe HS. Kymera’s partner Sanofi (SNY) is conducting the Phase 2 study in HS, and has initiated a second randomized Phase 2 trial in AD. Under the terms of the collaboration, dosing of the first patient in the HS trial generated a milestone payment of $40 million. “The initiation of dosing in the first Phase 2 trial of KT-474 in HS is an important step in the development of this molecule and a significant achievement for Kymera in demonstrating the potential of protein degradation to transform the treatment of complex, inflammatory diseases with small molecules,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. “Based on the encouraging KT-474 Phase 1 results, we believe that this molecule has the potential to offer HS patients a well-tolerated and effective oral drug. We look forward to sharing additional updates as our partner Sanofi advances this program, including dosing the first patient in the second Phase 2 trial in AD later this quarter.”